CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net income (loss)	$ 599	$ (2,306)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Net (gain) loss from securities transactions	(1,290)	4,402
Purchases of securities	(1,519)	(1,279)
Proceeds from sales of securities	715	20
Payments to cover securities sold, not yet purchased	(459)	(635)
Proceeds from securities sold, not yet purchased	2,141
Changes in receivables and payables relating to securities transactions	(858)	2,292
Changes in unrealized gains/losses on derivative contracts	(125)	(3,827)
Depreciation and amortization	127	121
Deferred taxes	(18)	(144)
Other, net	10	57
Changes in other operating assets and liabilities	126	(74)
Net cash used in operating activities	(551)	(1,373)
Cash flows from investing activities:
Capital expenditures	(47)	(53)
Acquisition of businesses, net of cash acquired	(20)	(1)
Purchases of investments		(254)
Proceeds from sale of investments	182
Other, net	1	(16)
Net cash provided by (used in) investing activities	116	(324)
Cash flows from financing activities:
Investment segment contributions from non-controlling interests	40	1
Partnership contributions	182	7
Dividends and distributions to non-controlling interests in subsidiaries		(23)
Proceeds from Holding Company senior unsecured notes	750	866
Repayments of Holding Company senior unsecured notes	(750)	(1,350)
Proceeds from subsidiary borrowings	177	1,368
Repayments of subsidiary borrowings	(180)	(848)
Other, net	(5)	(14)
Net cash provided by financing activities	214	7
Effect of exchange rate changes on cash and cash equivalents and restricted cash and restricted cash equivalents	6	2
Net decrease in cash and cash equivalents and restricted cash and restricted cash equivalents	(215)	(1,688)
Cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of period	3,291	4,945
Cash and cash equivalents and restricted cash and restricted cash equivalents, end of period	3,076	3,257
Icahn Enterprises Holdings
Cash flows from operating activities:
Net income (loss)	599	(2,306)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Net (gain) loss from securities transactions	(1,290)	4,402
Purchases of securities	(1,519)	(1,279)
Proceeds from sales of securities	715	20
Payments to cover securities sold, not yet purchased	(459)	(635)
Proceeds from securities sold, not yet purchased	2,141
Changes in receivables and payables relating to securities transactions	(858)	2,292
Changes in unrealized gains/losses on derivative contracts	(125)	(3,827)
Depreciation and amortization	127	121
Deferred taxes	(18)	(144)
Other, net	10	57
Changes in other operating assets and liabilities	126	(74)
Net cash used in operating activities	(551)	(1,373)
Cash flows from investing activities:
Capital expenditures	(47)	(53)
Acquisition of businesses, net of cash acquired	(20)	(1)
Purchases of investments		(254)
Proceeds from sale of investments	182
Other, net	1	(16)
Net cash provided by (used in) investing activities	116	(324)
Cash flows from financing activities:
Investment segment contributions from non-controlling interests	40	1
Partnership contributions	182	7
Dividends and distributions to non-controlling interests in subsidiaries		(23)
Proceeds from Holding Company senior unsecured notes	750	866
Repayments of Holding Company senior unsecured notes	(750)	(1,350)
Proceeds from subsidiary borrowings	177	1,368
Repayments of subsidiary borrowings	(180)	(848)
Other, net	(5)	(14)
Net cash provided by financing activities	214	7
Effect of exchange rate changes on cash and cash equivalents and restricted cash and restricted cash equivalents	6	2
Net decrease in cash and cash equivalents and restricted cash and restricted cash equivalents	(215)	(1,688)
Cash and cash equivalents and restricted cash and restricted cash equivalents, beginning of period	3,291	4,945
Cash and cash equivalents and restricted cash and restricted cash equivalents, end of period	$ 3,076	$ 3,257